Research Article| Volume 36, ISSUE 5, P711-721, May 01, 2014

Download started.


Evaluation of the Efficacy and Tolerability of Fixed-Dose Combination Therapy of Azilsartan and Amlodipine Besylate in Japanese Patients With Grade I to II Essential Hypertension



      Guidelines for the management of hypertension recommend using drugs with different mechanisms of action in antihypertensive regimens that include simple single-pill fixed-dose combination (FDC) products.


      The objective of this study was to compare the efficacy and tolerability of the FDC of azilsartan (AZI) and amlodipine besylate (AML) with those of AZI monotherapy and AML monotherapy in Japanese patients with grade 1 to 2 essential hypertension.


      This was a multicenter, randomized, double-blind, parallel-group study. After receiving placebo during a 4-week run-in period in a single-blind manner, patients were randomized to receive 1 of the following 5 treatments for 8 weeks: FDC containing AZI 20 mg and AML 5 mg (AZI/AML 20/5 mg), FDC containing AZI 20 mg and AML 2.5 mg (AZI/AML 20/2.5 mg), AZI 20 mg, AML 5 mg, or AML 2.5 mg once daily in a fasting or fed state. The primary end point was the change from baseline (week 0) in the seated trough diastolic blood pressure at week 8 (last observation carried forward [LOCF]), and the secondary end point was the change from baseline in the seated trough systolic blood pressure at week 8 (LOCF). Tolerability was assessed based on adverse events, vital signs, and physical examination findings.


      Of the 800 patients who provided informed consent, 603 were randomized to receive AZI/AML 20/5 mg (150 patients), AZI/AML 20/2.5 mg (151 patients), AZI 20 mg (151 patients), AML 5 mg (75 patients), or AML 2.5 mg (76 patients). The mean baseline systolic/diastolic blood pressure was 160.7/100.3 mm Hg. The mean change from baseline in seated blood pressure at week 8 (LOCF) was −35.3/−22.3 mm Hg in the AZI/AML 20/5 mg group and −31.4/−19.2 mm Hg in the AZI/AML 20/2.5 mg group, indicating a reduction significantly greater than that in corresponding monotherapy groups (−21.5/−13.9 mm Hg in the AZI 20 mg group, −26.4/−15.5 mm Hg in the AML 5 mg group, and −19.3/−11.6 mm Hg in the AML 2.5 mg group; p < 0.0001 for all contrast tests). No remarkable difference was found in the incidences of adverse events, vital signs, and physical examination findings among the treatment groups.


      This study found that the FDC of AZI/AML 20/5 mg and 20/2.5 mg exhibited greater antihypertensive effects compared with each monotherapy. The FDC of AZI/AML had a similar safety profile to that of each monotherapy and was tolerable to Japanese patients with grade 1 to 2 essential hypertension.

      Japan Pharmaceutical Information Center registration

      Japic CTI-111606.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Teramoto T.
        • Fujita T.
        Japan Guideline Assessment Panel 2 (J-GAP2) [in Japanese].
        Prog Med. 2010; 30: 1437-1449
        • Ogihara T.
        • Kikuchi K.
        • Matsuoka H.
        • et al.
        The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009).
        Hypertens Res. 2009; 32: 3-107
        • Rakugi H.
        • Enya K.
        • Sugiura K.
        • et al.
        Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study.
        Hypertens Res. 2012; 35: 552-558
      1. World Medical Association. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Accessed December 16, 2013.

        • Gerbino P.P.
        • Shoheiber O.
        Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents.
        Am J Health Syst Pharm. 2007; 64: 1279-1283
        • Schroeder K.
        • Fahey T.
        • Ebrahim S.
        How can we improve adherence to blood pressure-lowering medication in ambulatory care? systematic review of randomized controlled trials.
        Arch Intern Med. 2004; 164: 722-732
        • Gupta A.K.
        • Arshad S.
        • Poulter N.R.
        Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis.
        Hypertension. 2010; 55: 399-407
        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • et al.
        The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
        JAMA. 2003; 289: 2560-2572
        • Task Force for the management of arterial hypertension of the European Society of Hypertension
        2013 ESH/ESC guidelines for the Management of Arterial Hypertension.
        Blood Press. 2013; 22: 193-278
        • Miura K.
        • Nakagawa H.
        • Ohashi Y.
        • et al.
        Four blood pressure indexes and the risk of stroke and myocardial infarction in Japanese men and women: a meta-analysis of 16 cohort studies.
        Circulation. 2009; 119: 1892-1898
        • Lawes C.M.
        • Bennett D.A.
        • Parag V.
        • et al.
        Blood pressure indices and cardiovascular disease in the Asia Pacific region: a pooled analysis.
        Hypertension. 2003; 42: 69-75
        • Inoue R.
        • Ohkubo T.
        • Kikuya M.
        • et al.
        Predicting stroke using 4 ambulatory blood pressure monitoring-derived blood pressure indices: the Ohasama Study.
        Hypertension. 2006; 48: 877-882
        • Tomlinson B.
        • Woo J.
        • Thomas N.
        • et al.
        Randomized, controlled, parallel-group comparison of ambulatory and clinic blood pressure responses to amlodipine or enalapril during and after treatment in adult Chinese patients with hypertension.
        Clin Ther. 2004; 26: 1292-1304
        • Eguchi K.
        • Kario K.
        • Hoshide Y.
        • et al.
        Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients.
        Am J Hypertens. 2004; 17: 112-117
        • Staessen J.A.
        • Thijs L.
        • Fagard R.
        • et al.
        Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators.
        JAMA. 1999; 282: 539-546
        • Kikuya M.
        • Ohkubo T.
        • Asayama K.
        • et al.
        Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study.
        Hypertension. 2005; 45: 240-245
        • Asayama K.
        • Ohkubo T.
        • Kikuya M.
        • et al.
        Prediction of stroke by home “morning” versus “evening” blood pressure values: the Ohasama study.
        Hypertension. 2006; 48: 737-743